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Abstract
Clinical observations and mouse models have suggested that inflammation can be pro-tumorigenic. Since chemokines are
critical in leukocyte trafficking, we hypothesized that chemokines play essential roles in inflammation-associated cancers.
Screening for 37 chemokines in prostate cancer cell lines and xenografts revealed CXCL16, the ligand for the receptor
CXCR6, as the most consistently expressed chemokine. Immunohistochemistry and/or immunofluorescence and confocal
imaging of 121 human prostate specimens showed that CXCL16 and CXCR6 were co-expressed, both on prostate cancer
cells and adjacent T cells. Expression levels of CXCL16 and CXCR6 on cancer cells correlated with poor prognostic features
including high-stage and high-grade, and expression also correlated with post-inflammatory changes in the cancer stroma
as revealed by loss of alpha-smooth muscle actin. Moreover, CXCL16 enhanced the growth of CXCR6-expressing cancer and
primary CD4 T cells. We studied expression of CXCL16 in an additional 461 specimens covering 12 tumor types, and found
that CXCL16 was expressed in multiple human cancers associated with inflammation. Our study is the first to describe the
expression of CXCL16/CXCR6 on both cancer cells and adjacent T cells in humans, and to demonstrate correlations between
CXCL16 and CXCR6 vs. poor both prognostic features and reactive changes in cancer stoma. Taken together, our data
suggest that CXCL16 and CXCR6 may mark cancers arising in an inflammatory milieu and mediate pro-tumorigenic effects
of inflammation through direct effects on cancer cell growth and by inducing the migration and proliferation of tumor-
associated leukocytes.
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Introduction
Recent mouse models have made a functional link between
cancer and inflammation [1–3], providing evidence for a tumor-
promoting activity for leukocytes as originally suggested by Rudolf
Virchow [4,5]. Human prostate cancer has been postulated to
arise from precancerous processes associated with inflammation,
such as proliferative inflammatory atrophy (PIA) [6], which are
lesions found adjacent to prostate cancer that are proposed to lead
to prostatic intraepithelial neoplasia (PIN) or cancer [7].
Among the factors important for inflammation are chemokines
– chemotactic cytokines that mediate leukocyte recruitment [8].
Diverse roles have been reported for chemokines in tumor biology,
including direct effects on cancer cells, such as on transformation,
survival, and proliferation, and indirect effects, such as in
angiogenesis and in recruiting leukocytes to tumor sites [9–11].
In view of the recent evidence for possible pro-tumorigenic activity
of leukocytes, we hypothesized that inflammatory chemokines,
either produced by the tumor cells or by tumor-associated
leukocytes, might, contrary to the standard viewpoint, contribute
to malignant progression by enhancing leukocyte recruitment.
In the studies described below, a screen for expression of 37
chemokines in prostate cancer cell lines and xenografts revealed
high-level expression of CXCL16, an unusual chemokine that
exists in both transmembrane and soluble forms [12,13], and that
can also function as a scavenger receptor for oxidized lipoprotein
and bacteria [14]. CXCL16 expression has been associated with a
number of human inflammatory diseases including rheumatoid
arthritis [15,16], interstitial lung diseases [17,18], atherosclerosis
[19–23], coronary artery disease [24,25] and liver injury [26–30].
The CXCL16 receptor, CXCR6, has been reported to be
expressed on Th1 cells [31], on tumor infiltrating lymphocytes
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6695[32], and on a variety of leukocytes in inflamed tissue sites [33,34],
and can serve as a co-receptor for HIV-1 [32,35].
Our study suggests direct roles for CXCL16-CXCR6 on
prostate cancer by demonstrating co-localization of CXCL16
and CXCR6 on cancer cells, finding significant positive cor-
relations between expression of CXCL16 and CXCR6 vs. the
stage and grade of prostate cancer, and showing that CXCL16 can
stimulate the growth of prostate cancer cell lines transfected to
express CXCR6.
Our studies on the relation between CXCL16/CXCR6,
inflammation, and cancer show that CXCL16 is up-regulated on
pre-neoplastic lesions associated with inflammation, that the
expression of CXCL16 and CXCR6 can be induced in prostate
epithelium by inflammatory cytokines, and that CXCL16/
CXCR6 are highest in those prostate cancer cells surrounded by
reactive, i.e. post-inflammatory stroma. We also showed that T
cells adjacent to cancer cells express CXCL16/CXCR6, that
CXCL16 is produced preferentially by CD4
+CXCR6
+ T cells,
and that CXCL16 can enhance the proliferation of T cells. Finally
we demonstrate CXCL16 in multiple human cancers associated
with inflammation. Together our data suggest that CXCL16 and
CXCR6 may contribute to tumor progression directly through
effects on cancer cell growth, and indirectly, by enhancing
leukocyte recruitment and proliferation and the interactions
between leukocytes and pre-malignant/malignant cells.
Results
Malignant prostate cells express CXCL16 and CXCR6
In order to investigate the roles of chemokines in prostate
cancer, we screened prostate cancer cell lines and xenografts for
expression of mRNAs for 37 chemokines, and found that the
mRNA for CXCL16 was the most consistently expressed
(Figure 1A, B). Cell surface expression of CXCL16 was found
on PC3, DU145 and 22Rv1 prostate cell lines (Figure 1C).
Immunohistochemical analysis of prostate tissue showed low or no
staining for CXCL16 and low staining for its receptor, CXCR6 in
normal human prostate epithelium, but prominent expression in
the cancer (Figure 1D). In addition, a correlation between the
expression levels of CXCL16 and CXCR6 was found by analyzing
an array of forty cases of prostate cancer, and CXCL16 and
CXCR6 can be shown to be co-expressed on individual cancer
cells by immunofluorescent confocal microscopy (Figure 1E).
Expression of CXCL16 and CXCR6 correlates with cancer
stage and grade
The stage (I-IV) and grade (Gleason score) of prostate cancer
are determined at diagnosis, and were reported by the supplier for
the cases used in the arrays. Higher stage corresponds to greater
anatomic extension of the cancer, and Gleason score describes
histological characteristics that correlate with clinical outcome.
Gleason scores of 2–4 are low-grade, scores 5–7 are moderate-
grade, and scores 8–10 are high-grade prostate cancer. Analysis of
the 40-case array for levels of staining for CXCL16 and CXCR6
revealed that their expression by the cancer cells correlated with
both high-stage and high-grade prostate cancer (Figure 2A).
A role for CXCL16/CXCR6 in the proliferation of prostate
cancer cells
The co-expression of CXCL16 and CXCR6 on prostate cancer
cells, and their correlation with cancer stage and grade, suggested
that the ligand and receptor might enhance proliferation through
an autocrine pathway. To investigate this possibility, we
transfected PC3 cells with a CXCR6-YFP plasmid that encodes
a CXCR6 C-terminal fusion protein with an enhanced yellow-
green florescent protein (YFP), and incubated the cells with
CXCL16. As shown in Figure 2B, the number of CXCR6-YFP
+
cells increased, vs. control CXCR6-YFP
2 cells, as a function of the
concentration of CXCL16. We also analyzed the relationship
between expression level of CXCR6-YFP and the response to
CXCL16. We found that while cells expressing the highest levels
of CXCR6-YFP were those most responsive to CXCL16,
CXCL16 increased the proliferation even of those cells that were
CXCR6-YFP
low (Figure 2C). Consistent with these in vitro data,
cancer cells expressing Ki67, a cellular marker for proliferation,
also expressed both CXCL16 and CXCR6 (Figure 2D).
Expression of CXCL16/CXCR6 is associated with
inflammation
Immunohistochemical analysis of multiple specimens from
radical prostatectomies showed prominent expression of CXCL16
and CXCR6 in chronic prostatitis and in atrophy with associated
chronic prostatitis (PIA), as well as in prostatic intraepithelial
neoplasia (PIN) and cancer, suggesting that expression of CXCL16
andCXCR6on prostate epithelial cellsis related toinflammation in
addition to any association with malignancy per se (Figure 3A). We
investigatedthisrelationshipinvitrobytreatingculturesofepithelial
(PrEC) and stromal cells (PrSC) from normal prostates with
inflammatory cytokines. TNF-a and IFN-c, particularly in
combination, induced CXCL16 mRNA and CXCL16 secretion
by PrEC (but not stromal cells) (Figure 3B, C) – and led to dramatic
up-regulation in PrEC of the mRNA for CXCR6 (Figure 3D).
In addition to the association of CXCL16/CXCR6 with
inflammatory infiltrates in prostate, our initial impression from
analyzing more than 80 cases of prostate cancer was that
expression of CXCL16 was highest in cancer cells surrounded
by reactive stroma. Stroma is described as ‘‘reactive’’ if it shows
increases in myofibroblasts, fibroblast to smooth muscle ratio and
local vascular density [36]. This occurs following inflammation,
and identifies cancers, now relatively poor in inflammatory cells,
that have arisen in an inflammatory micro-environment. We
confirmed our initial impression by staining serial sections for
CXCL16, CXCR6 and alpha smooth muscle actin (a-SMA), a
marker for smooth muscle cells, which are lost from reactive
stroma. We found an association between loss of smooth muscle
cells and high expression of CXCL16 and CXCR6 (Figure 3E),
which was confirmed by scoring samples in the 40-case array for
a-SMA, CXCL16, and CXCR6 (Figure 3F). These data
supported the association between expression of CXCL16 and
CXCR6 and evidence of prior inflammation in the tumor micro-
environment. Together, the data in Figure 3 suggest a strong
correlation between expression of CXCL16/CXCR6 and inflam-
mation at all stages in the evolution of prostate cancer.
A role for CXCL16/CXCR6 in interactions between cancer
cells and T cells
The possible direct effects of CXCL16/CXCR6 on prostate
cancer cells notwithstanding, because CXCR6 is best described as
a T cell chemokine receptor, we investigated activities for
CXCL16/CXCR6 on prostate-cancer associated T cells that
might contribute indirectly to the formation and growth of the
cancer. Immunofluorescent staining revealed that both CXCL16
and CXCR6 are expressed on CD3
+ cells adjacent to cancer cells
(Figure 4A). Of interest, we found that some CD3
+ cells also
stained for Ki67 (Figure 4B), demonstrating T cell proliferation at
the tumor site. Moreover, double staining for CXCR6 and Ki67
revealed inflammatory cells that were positive for both (Figure 4C).
CXCL16/CXCR6 Promote Cancer
PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6695Figure1.CXCL16isthemostprevalentchemokineexpressedinprostatecancercelllinesandxenografts andits expression correlates
withlevels ofCXCR6on cancercells. (A)Theexpression of mRNAsfor 37chemokines was studied by RT-PCR in xenografts (CWR22, WISH PC14)and
prostate tumor cell lines (PC3, DU145, LNCaP). Systematic and non-systematic names for chemokines are shown. Amplicons were analyzed by agarose
gel electrophoresis and visual inspection after staining with ethidium bromide. Sequences of primers are available on request. The levels of expression
were evaluatedasfollows: noexpression (2), lowexpression(2+),moderateexpression(+),andhigh expression (++).Dependingonthechemokine,the
analysis was done from one to four times. (B) mRNA expression of chemokines in prostate cancer cell lines. The expression of mRNAs for 14 chemokines
was studied by real-time RT-PCR on four prostate tumor cell lines (PC3, DU145, LNCaP, 22Rv1). The value of 2
-DCT was calculated and then normalized to
the highest number for a given cell line, which was given the value of 100, where DCT=CT (chemokine)-CT (GAPDH). Numbers are averages of two
determinations from one representative experiment of two performed. (C) Flow cytometric analysis of surface expression of CXCL16 on prostate cancer
cell lines. PC3, 22Rv1 and DU145 cells were incubated without primary antibody (black shading), with goat anti-human CCL4 as an additional control
(light gray line), or with goat anti-human CXCL16 (dark gray line) and then stained with rabbit anti-goat IgG-FITC. Data are from one representative
experiment of three performed. (D) Staining for CXCL16 and CXCR6 in prostatectomy specimens using DAB (brown) for detection is shown for: normal
prostate and prostate cancer. Panels are representative of over 80 prostate cancers cases examined. Each panel includes an H&E stain on the left. (E)
Arrays containing prostate cancer tissue from 40 patients were stained for CXCL16 and CXCR6. (I) Samples were analyzed as described in Materials and
Methods, grouped according to scores for CXCL16 on the X-axis (n=samples in each CXCL16 group), and mean scores for CXCR6 expression were
calculated. Error bars show SEM. Cross-bars indicate comparisons that are significant. *, p,0.05 and **, p,0.01. (II) Immunofluorescence and confocal
imaging of a section showing prostate cancer cells displays anti-CXCL16 (488 tyramide) as green, anti-CXCR6 (594 tyramide) as red, and nuclear staining
with Hoechst 33258 as blue.Double staining in yellow showsco-localization. Panelsarerepresentativeof more than 15 casesof prostatecancer.Original
magnifications are noted on these and all subsequent photomicrographs.
doi:10.1371/journal.pone.0006695.g001
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in an autocrine fashion to enhance T cell proliferation analogous
to effects on cancer cells. To determine whether or not CXCL16
could be produced by CXCR6
+ cells, which are found only in the
effector/memory subset, we sorted populations of peripheral blood
CD4
+ T cells based on the expression of memoryand naı ¨ve markers
and CXCR6. After activation ex vivo, we found that the mRNA for
CXCL16 was induced preferentially within the effector/memory
subset and, within that subset, in the cells expressing CXCR6
(Figure 5A). We next tested the potential activities of CXCR6 on T
cells by transfecting the Jurkat E6.1 T cell line with DNA encoding
CXCR6-YFPorGFP.CXCR6-YFP
+,butnotCXCR6-YFP
2cells,
migrated to CXCL16 in a Gi/o-protein dependent fashion
(Figure 5B), and showed a progressive increase in cell numbers
with increasing doses of CXCL16, but not to a control chemokine
(Figure 5C). CXCL16 had no effect on cells transfected to express
GFP as an additional control (data not shown). CXCL16/CXCR6
enhanced proliferation per se, since we saw no effects on cell death
(Figure 5D) and found an increase specifically within the population
of cells that were dividing (Figure 5E).
Moreover, when we examined the effect of plate-bound
CXCL16 on the proliferation of CD3-activated primary CD4 T
cells, we found a significant stimulatory effect on proliferation that
was inhibited by treating with pertussis toxin or antibodies against
CXCR6 or CXCL16 (Figure 6A). It is notable, given that
CXCL16 is synthesized as a transmembrane chemokine, that
Figure 2. Roles for CXCL16 and CXCR6 in prostate cancer stage, grade and cell growth. (A) Arrays containing prostate cancer tissue from
40 patients were stained for CXCL16 and CXCR6. Samples were scored for CXCL16 and CXCR6 expression as described in Materials and Methods.
Samples were grouped according to stage or Gleason score (X-axes) as determined by the supplier, and mean scores for CXCL16 and CXCR6
expression were calculated. The number of samples (n) in each stage or Gleason score group is shown. Error bars show SEM. Cross-bars indicate
comparisons that are significant. *, p,0.05 and ***, p,0.001. (B) PC3 cells were transfected with the CXCR6-YFP plasmid, cultured for 48 hours
without chemokine (control, ctrl) or with 0.05–5 mg/ml CXCL16 and numbers of CXCR6-YFP
+ (R6YFP
+) vs. CXCR6YFP
2 (R6YFP
2) cells were counted as
described in Materials and Methods. Values were normalized to the control, untreated sample to yield the fold difference in cell number. Bars show
means6SEM combined from three experiments. **, p,0.01 and ***, p,0.001 vs. control values. (C) Following transfection with the CXCR6-YFP
plasmid, PC3 cells were cultured as in (B), without or with 5 mg/ml CXCL16. Left panel, gating is shown for separating untreated and CXCL16-treated
cells into ‘‘low’’ (L) or ‘‘high’’ (H) for CXCR6-YFP. Percentages of cells in the high gates are shown. One representative experiment is shown out of
three performed. Right panel, CXCR6-YFP
+low (CXCR6+low) and CXCR6-YFP
+high (CXCR6+high) cells from CXCL16-treated and control cultures were
counted after 48 hours as in (B). Data were combined from three experiments. *, p,0.05 and ***, p,0.001 vs. untreated cells. (D) Confocal imaging
displays anti-CXCL16 or anti-CXCR6 (488 tyramide) as green, anti-Ki67 (594 tyramide) as red, and nuclear staining with Hoechst 33258 as blue. Panel is
representative of more than 15 cases.
doi:10.1371/journal.pone.0006695.g002
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PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6695Figure 3. Inflammatory stroma and cytokines induce CXCL16 and CXCR6 on normal and malignant prostate cells. (A) Staining for
CXCL16 and CXCR6 in prostatectomy specimens using DAB (brown) for detection is shown for: chronic prostatitis, PIA and PIN. Panels are
representative of over 80 prostate cancer cases examined. Each panel includes an H&E stain on the left. (B) CXCL16 secreted by primary normal
epithelial cells (PrEC) and stromal cells (PrSC), and the DU145 and PC3 cell lines was measured 48 hours after no treatment (control), or treatment
with 5 ng/ml IFN-c and 0.5 mg/ml TNF-a alone and in combination. Bars show means6SEM from duplicate wells, of one representative experiment of
three performed for each of three donors (D1–D3). *, p,0.05 and **, p,0.01 vs. untreated cells. (C) CXCL16 mRNA expression in PrEC from three
donors and two prostate tumor cell lines (DU145 and PC3) treated with 5 ng/ml IFN-c and 0.5 mg/ml TNF-a alone and in combination were analyzed
using real-time RT-PCR. Values were normalized by setting the control sample with lowest expression equal to 1. Each bar represents the mean6SEM
obtained from duplicate wells, from one representative experiment of three performed. **, p,0.01 vs. untreated cells. (D) CXCR6 mRNA expression in
PrEC from three donors treated with 5 ng/ml IFN-c and 0.5 mg/ml TNF-a alone and in combination were analyzed using real-time RT-PCR. Values were
normalized by setting the sample with lowest expression equal to 1. **, p,0.01 vs. untreated cells. (E) Each row contains serial sections from the same
regions of prostatectomy specimens stained using DAB (brown) for aSMA, CXCL16, and CXCR6 including an H&E stain on the left. Panels are
representative of over 120 prostate specimens. (F) Separate slides of arrays containing prostate tissue from 40 patients were stained for aSMA,
CXCL16 and CXCR6 and scored as described in Material and Methods for aSMA in stroma and CXCL16 and CXCR6 in cancer cells. Samples were
grouped according to scores for CXCL16 or CXCR6 (n=samples in each group), and mean scores were calculated for aSMA in stroma. Data are
displayed and analyzed as in Fig. 1E.I. *, p,0.05.
doi:10.1371/journal.pone.0006695.g003
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had no effect (data not shown).
Despite the data for effects of CXCL16 on activated CD4
+ T
cells, we could not detect staining for CXCR6 using flow
cytometry on a large or increased percentage of these cells after
activation. However, in support of functional CXCR6 on these
cells, we found a significant increase in mRNA expression of
CXCR6 and (less so) of CXCL16 in CD3-activated cells
(Figure 6B), and an increase in the migration of the CD3-activated
cells to CXCL16 (Figure 6C). The dose response in Figure 6C has
the bell-shaped pattern typical for chemotaxis.
CXCL16 and/or CXCR6 are broadly expressed in
inflammation-associated cancers
In order to investigate the possibility of a more general
association between CXCL16 and inflammation-associated can-
cer, we studied the expression of CXCL16 in 582 cases of cancer
covering 12 tumor types (Figure 7). We found a bias for high
CXCL16 expression in cancers associated with inflammation:
ovary, breast, prostate, colon and liver cancers.
Discussion
Cancer arises from genetic mutations and epigenetic events in
the proliferating cells and changes in the tumor’s microenviron-
ment that includes capillaries, smooth muscle cells, fibroblasts and
inflammatory cells [4]. In 1863, the German physician Rudolf
Virchow noted leukocytes in neoplastic tissues and hypothesized
that cancer begins at sites of chronic inflammation [37].
Nonetheless, cancer immunologists have generally viewed leuko-
cytes as agents with the potential to limit or eliminate cancers [38].
Similarly, in their roles as mediators of leukocyte recruitment,
chemokines have been studied as stimulators of anti-cancer
immunity and inflammation [11,39,40].
Chronic inflammatory conditions have, however, been shown to
predispose to multiple cancer types and recurrent or chronic
inflammation has been implicated in a variety of human cancers
[5]. Recent mouse models have made a functional link between
cancer and inflammation, showing that deletion of immune cells
or immunoregulatory genes reduce cancer progression [1–3].
Together, these data raise the possibility of an additional role for
pro-inflammatory chemokines in cancer, namely as tumor
promoters.
We investigated prostate cancer, which is described as arising in
the context of inflammation. Our preliminary screen for
chemokine expression suggested a role for CXCL16, and we
found that both CXCL16 and CXCR6 were co-expressed on
cancer cells, that their levels of expression correlated with each
other, and that these levels also correlated with high-stage and
high-grade prostate cancer. In addition, CXCL16 enhanced
proliferation of prostate cancer cell lines expressing CXCR6.
Our data suggest possible direct effects of CXCL16/CXCR6 on
cancer cell growth and thereby on tumor development.
In a second aspect of our study, we investigated potential roles
for CXCL16/CXCR6 within the context of the postulated
contribution of inflammation to pre-malignant and malignant
disease in the prostate. We found high expression for CXCL16 in
chronic prostatitis, pre-neoplastic lesions, and primary prostate
cancer surrounded by reactive, i.e. post-inflammatory stroma.
Moreover, TNF-a and IFN-c induced the expression of CXCL16
and CXCR6 on primary prostate epithelial cells. In addition, we
found significant correlations between the presence of reactive
stroma and high-level expression of CXCL16 and CXCR6 in
cancer cells. These results suggested that up-regulation of
Figure 4. CXCL16 and CXCR6 are expressed by T cells in prostate tissue. (A, B) Confocal imaging shows anti-CXCL16 (A, left panel) or anti-
CXCR6 (A, right panel) or anti-Ki67 (B) as green (488 tyramide), anti-CD3 (594 tyramide) as red, and nuclear staining with Hoechst 33258 as blue.
Double staining in yellow shows co-localization. In (A), arrows point to cancer cells and T cells. Panels are representative of more than 15 cases for
each double-stain. (C) Staining for Ki67 and CXCR6 in a region of prostatitis using DAB (brown, two left panels) or immunofluorescence (right panel)
for detection. Confocal imaging shows anti-CXCR6 as green (488 tyramide) and anti-Ki67 as red (594 tyramide), and nuclear staining with Hoechst
33258 as blue. Panel is representative of more than 15 cases.
doi:10.1371/journal.pone.0006695.g004
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PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6695Figure 5. CXCL16 can mediate the migration and proliferation of T cells expressing CXCR6. (A) CD4
+ T cells were sorted into naı ¨ve
(CD45RO-), total effector/memory (CD45RO+), CD45RO
+CXCR6
2 (CXCR6-) and CD45RO
+CXCR6
+ (CXCR6+) subsets and stimulated with PMA and
ionomycin for 4 hours before measuring levels of CXCL16 mRNA by real-time RT-PCR. Values were normalized by setting the sample with lowest
expression equal to 1. The data are means from duplicate samples from one representative experiment out of three performed. (B) Jurkat E6.1 T cells
transfected with the CXCR6-YFP plasmid were analyzed for migration to CXCL16. Some samples were pre-incubated for two hours with 400 ng/ml
pertussis toxin as indicated. Numbers of YFP+ and YFP- migrating cells were analyzed by flow cytometry. Each bar represents the mean6SEM
obtained from triplicate wells, from one representative experiment of three performed. ***, p,0.001 vs. the corresponding control value.
(C) Following transfection with the CXCR6-YFP plasmid, Jurkat E6.1 T cells were cultured for 48 hours without chemokine (control, ctrl) or with 1 mg/
ml CXCL8 as an additional control, or with 0.05–5 mg/ml CXCL16 before counting numbers of CXCR6-YFP
+ vs. CXCR6-YFP
2 cells. Bars show
means6SEM combined from three different experiments. *, p,0.05 and ***, p,0.001. (D) Transfected cells were treated as in (C) and stained with
Annexin V and propidium iodide (PI) before counting numbers of CXCR6-YFP
+ cells within the subgroups as noted. Bars show means6SEM combined
from three experiments. **, p,0.01 and ***, p,0.001 vs. control untreated cells. (E) Following transfections with CXCR6-YFP plasmid, Jurkat E6.1 T
cells were loaded with 2 mM Far Red DDAO dye and cultured without chemokine (control, ctrl) or with 0.05–5 mg/ml CXCL16 or 1 mg/ml CXCL8.
Numbers of CXCR6YFP
+ vs. CXCR6YFP
+DDAO
2 (proliferated) and CXCR6YFP
+DDAO
+ (non-proliferated) cells were determined after 48 hours using
counting beads and flow cytometry. Bars show means6SEM from triplicate wells, from one representative experiment of three performed. ***,
p,0.001 and *, p,0.05 vs. control untreated cells.
doi:10.1371/journal.pone.0006695.g005
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with both current and previous inflammation in prostate stroma.
In a third part of our study, we investigated potential roles for
CXCL16 and CXCR6 on tumor-associated lymphocytes. We
found that CXCL16 and CXCR6 are expressed on T cells
adjacent to prostate cancer cells. We demonstrated that CXCL16
can be induced preferentially in CXCR6
+CD4
+ primary T cells,
and that Jurkat T cells transfected to express CXCR6 as well as
activated, primary CD4
+ T cells proliferated in the presence of
CXCL16. These data suggest the potential for both autocrine and
paracrine effects of CXCL16 on infiltrating T cells as well as on
pre-malignant and/or malignant prostate cells.
Finally, to investigate a more general association between
CXCL16 and inflammation-associated cancers, we studied the
expression of this chemokine in specimens from multiple types of
human cancers. We found high expression levels of CXCL16 in
cancers of the ovary, breast, prostate, colon and liver – all cancers
described as arising in the context of inflammation.
CXCL16 has been previously described on human gliomas,
colon and breast cancer, and CXCR6 was reported in
nasopharyngeal cancers and melanoma [41–46]. Several addi-
tional papers have recently appeared investigating CXCL16 and/
or CXCR6 in cancer [45–50]. Several of these reports focused on
CXCR6 in prostate cancer, and like ours showed high expression
of CXCR6 in prostate cancer cells [47–49]. One paper, also like
ours, demonstrated a positive correlation between CXCR6 levels
and Gleason scores, reported CXCL16 expression in prostate
cancers, and showed increased secretion of CXCL16 from
prostate cell lines after treating with TNF-a [47]. A second paper
showed effects on invasion of prostate lines to soluble CXCL16
[48]. A third paper demonstrated effects of CXCR6 on the growth
of prostate cancer cell lines in mice [49]. Overall, our findings
suggesting pro-tumorigenic roles for CXCL16 and CXCR6 in
prostate cancer are consistent with these published reports. These
manuscripts did not, however, investigate expression of, or roles
for CXCL16/CXCR6 in cancer-associated inflammation or
leukocytes, or in the pre-malignant stages of prostate cancer. Of
additional related interest, a recent study reported induction of
CXCL16 in bone stroma conditioned by prostate cancer cells, and
elevated serum levels of CXCL16 in patients with metastatic
prostate cancer [50].
It is notable that in experiments using colon carcinoma cell
lines, membrane-bound CXCL16 inhibited cell proliferation [45]
and in a study of CXCL16 in colon cancer, no association was
found between CXCL16 expression and cancer stage - but instead
a positive correlation was reported between CXCL16 expression
and patient survival [42]. This latter observation contrasts with
our findings on the positive correlations between expression of
CXCL16 and CXCR6 and high stage and grade for prostate
cancer, and may reflect variable roles for inflammation in cancer
depending on tumor type and stage of tumor development.
To date, multiple chemokines have been described having roles
in tumor growth and metastasis [51]. Our study is the first to
describe expression of the chemokine CXCL16 and its receptor
CXCR6 on both cancer cells and adjacent T cells in human
cancer and demonstrate correlations between expression of
CXCL16 and CXCR6 and tumor progression. By demonstrating
a correlation between this chemokine-receptor pair and reactive,
post-inflammatory stroma, our study is also the first to make a
connection between expression of a chemokine and its receptor
and changes in the microenvironment of human cancer.
Taken together, our data suggest that CXCL16 and CXCR6,
expressed by both inflammatory cells and cancer cells in human
cancers, may be components of inter-related paracrine and
Figure 6. CXCL16 can mediate the proliferation and migration
of CD3-activated primary CD4 T cells. (A) CD4
+ T cells purified
from elutriated lymphocytes from healthy donors were stimulated for 3
days with plate-bound anti-CD3 (OKT3, 10 mg/ml) with or without 5 mg/
ml plate-bound CXCL16 (bL16). Treatments of anti-CD3-activated cells
with PTX, anti-CXCR6 (aR6) and anti-CXCL16 (aL16) without bL16 were
done as controls. Mouse IgG (mIgG) and rat IgG (rIgG) were used as
controls for anti-CXCR6 antibody and anti-CXCL16 antibody, respec-
tively. Bars show means6SEM from one representative experiment out
of five, using five donors. Anti-CXCL16 was used in a total of four, and
anti-CXCR6 in two experiments. ns, not significant and ***, p,0.001. (B)
CXCR6 and CXCL16 mRNAs were measured by real-time RT-PCR in CD3-
activated and non-activated CD4
+ T cells after 3 days. Values were
normalized by setting the non-activated sample with lowest expression
equal to 1. Bars show means6SEM combined from duplicate wells from
seven different donors. **, p,0.01 and ***, p,0.001 vs. non-activated
cells. (C) Anti-CD3-activated or nonactivated CD4
+ T cells were analyzed
for migration to CXCL16, expressed as percentages of input cells
migrating. Each bar represents the mean6SEM obtained from triplicate
wells from a total of three experiments performed. ***, p,0.001 on
cross bars are indicated for comparisons between activated cells - 0 vs.
50 ng/ml CXCL16 and 50 ng/ml vs. 500 ng/ml CXCL16.
doi:10.1371/journal.pone.0006695.g006
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cytokines and chemokines. CXCL16 could enhance tumor growth
directly through CXCR6-mediated effects on the proliferation/
survival of cancer cells and indirectly through enhanced
recruitment and proliferation/survival of cytokine-producing T
cells (Figure 8). Our data correlating CXCL16 and CXCR6 with
stage and grade of prostate cancer provide additional evidence
that, in the prostate, inflammation is tumorigenic, and should
stimulate the increasing interest in a possible tumor-promoting
role specifically for CD4
+ T cells [52]. Although we have focused
on prostate cancer, our findings that multiple inflammation-
associated human cancers express high levels of CXCL16 and
CXCR6 suggest that this chemokine/receptor pair may serve as a
marker of current or prior inflammation within cancers, thereby
providing a tool that can be broadly applied to studying the
relationships between inflammation and the behaviors of various
malignancies.
Methods
Cells and Tissues
PrEC and PrSC were purchased from Cambrex Bio Science,
Walkersville, MD, and the PC3, DU145, 22Rv1, LNCaP and
Jurkat cell lines were purchased from American Type Culture
Collection, Manassas, VA. Cells were grown as instructed by the
suppliers.
These samples were obtained from the clinical frozen tissue
archives of the Department of Pathology at The University of
Virginia: Breast (12 cases), prostate (13 cases), colon (9 cases),
ovary (12 cases) and lung (14 cases). There were no specific
inclusions or exclusions. The samples were taken from the archives
with all identifiers removed after review and approval by the
Institutional Review Board for Health Sciences Research (IRB-
HSR) at The University of Virginia, which granted a waiver for
obtaining informed consent. Additional prostate tissue samples (13
Figure 7. CXCL16 is highly expressed in multiple inflammation-associated cancers. (A) * The intensity of CXCL16 staining was scored as
described in Materials and Methods. The % of cases staining high is shown for each cancer type. ** RCC, renal cell carcinoma; GBM, glioblastoma
multiforme. (B) CXCL16 expression in arrays of multiple human cancers by immunohistochemistry using AEC (red) or DAB (brown) for detection.
Panels are representative of the numbers of specimens of the various cancers as listed in (A).
doi:10.1371/journal.pone.0006695.g007
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University of Texas, San Antonio (Tissue Bank #HSC20050234H
IRB Protocol #45-8000-234). There were no specific inclusions or
exclusions. The samples were taken from the archives with all
identifiers removed after review and approval by the Tissue Bank
and Data Base for Urologic Diseases of the National Cancer
Institute, and the University of Texas, San Antonio IRB, which
granted a waiver for obtaining informed consent.
Elutriated lymphocytes were obtained from healthy donors by
the Department of Transfusion Medicine, under a protocol (99-
CC-0168) approved by the IRB of the Clinical Center, NIH. All
blood components collected under this protocol are used for
research purposes, to which donors provide written consent. Some
tissue arrays were from the Tissue Array Research Program
(TARP), Center for Cancer Research, National Cancer Institute
and some were purchased from Imgenex, San Diego, CA. The
TARP is a biobank. For the TARP arrays, tissues were obtained
retrospectively and anonymously from surgical pathology speci-
mens. Patients consented to donation, and samples were
transferred to TARP without identifiers. This use was considered
exempt from IRB review by the NIH Office of Human Subjects
Research. The numbers of samples (as presented also in Figure 7)
and the sources for each tumor type were: head and neck cancer -
19 cases, TARP array; thyroid cancer - 25 cases, TARP array;
renal cell carcinoma (RCC)- 28 cases, TARP array; melanoma- 29
cases, TARP array; lymphoma- 28 cases, TARP array; lung
cancer - 84 cases total - 70 cases from TARP array and 14 cases
from University of Virginia; glioblastoma (GBM) – 20 cases,
TARP array; ovarian cancer – 62 cases total - 50 from TARP
array and 12 from University of Virginia; breast cancer - 42 cases
total- 30 cases from TARP array and 12 cases from University of
Virginia; colon cancer - 69 cases total- 60 cases from TARP array
and 9 cases from University of Virginia; prostate cancer -121 cases
total- 75 from TARP array, 13 from University of Texas, 13 from
University of Virginia, and 20 from Imgenex commercial array;
liver cancer - 55 cases, Imgenex commercial array.
Antibodies and Cytokines
All antibodies were against human antigens. For immunohis-
tochemistry the following antibodies were used: goat anti-
CXCL16 (biotinylated and non-biotinylated, R&D Systems,
Minneapolis, MN), rabbit anti-CXCR6 (GeneTex, San Antonio,
TX), rabbit anti-CD3, mouse anti-CD3 (F7.2.38), mouse anti-
alpha smooth muscle actin (aSMA) (1A4), and mouse anti-Ki-67
(MIB-1) (DakoCytomation, Carpinteria, CA). For each of these
antibodies, the corresponding control antibodies, goat, rabbit or
mouse IgG were used (R&D Systems). For FACS sorting and/or
analysis the following antibodies were used: mouse anti-CXCR6-
PE (R&D Systems), mouse anti-CD4-APCCy7 and mouse anti-
CD45RO-PECy5 (BD Pharmingen, San Diego, CA). For CD4
proliferation experiments the following antibodies were used:
mouse anti-CXCR6 and rat anti-CXCL16 and the corresponding
control mouse or rat IgG’s (R&D Systems). Cytokines were
purchased from R&D Systems. The hybridoma producing anti-
CD3 (clone OKT3) was obtained from Ortho Biotech (Raritan,
NJ) and antibody was purified from ascites by the Research
Technologies Branch, NIAID.
Real Time RT-PCR
Target cDNA sequences were amplified using ‘‘inventoried’’
primer-probe sets that spanned exon boundaries and using
fluorescence-based real-time detection instrumentation (ABI
PRISM 7700) from Applied Biosystems, Foster City, CA. Relative
gene expression was calculated using the delta-CT method [53]. A
control mRNA, for either glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) or b2-microglobulin, was analyzed in each run.
Primers/probes produced exponential amplification curves.
Immunohistochemistry
Tissue samples were either snap-frozen or formalin/ethanol-
fixed and paraffin-embedded. Frozen tissue was fixed in formalin
prior to staining. Paraffin embedded sections were treated for
antigen retrieval (Target Retrieval Solution, DakoCytomation). If
necessary, endogenous peroxidase was inactivated using Peroxi-
dase Blocking Reagent, followed by blocking endogenous biotin
using the Avidin-Biotin Blocking kit (both from DakoCytomation).
In some cases, biotinylated rabbit anti-goat IgG secondary
antibody was used, and detection was done using a standard
avidin–biotin horseradish peroxidase procedure according to the
manufacturer’s instructions (Zymed Laboratories, San Francisco,
CA). 3-amino-9-ethylcarbazole (AEC) or 3,39-diaminobenzedine
(DAB) (DakoCytomation) was used for color development, and
sections were counterstained with hematoxylin. For negative
controls, sections were stained using rabbit IgG or biotinylated
goat IgG (R&D Systems) as appropriate. Staining for CXCL16,
CXCR6 and aSMA were scored separately by a single pathologist
(J.W.G) blind to clinical data and to results with other stains. For
CXCL16 and CXCR6, expression was scored from 0–3, with 0
being negative and 3 the highest level of staining intensity. For
aSMA, the percentage of stromal cells staining positive for aSMA
was scored with 0=0–25%, 1=25–50%, 2=50–75%, and
3=75–100%. For analyzing CXCL16 expression in multiple
tumor types (Figure 7), the intensity of CXCL16 staining was
scored as ‘‘high’’ (scores 2, 3) or ‘‘low’’ (scores 0, 1) by visual
inspection by a single pathologist (J.W.G) and confirmed by a
second (S.M.H).
Immunofluorescence
Immunofluorescence was done using Alexa Flour 488 tyramide
and Alexa Flour 594 tyramide (Invitrogen, Eugene, OR). For
Figure 8. CXCL16 and CXCR6 establish positive feedback loops
contributing to the progression of inflammation-associated
cancers. Secretion of CXCL16 from pre-cancer or cancer cells leads to
CXCR6-mediated recruitment of leukocytes. Cytokines such as TNF-a
and IFN-c produced by these cells in turn induce expression of CXCL16
and CXCR6, creating a positive feedback loop that enhances
tumorigenesis – directly, through effects on the growth of pre-cancer
and cancer cells, and indirectly, by increasing the migration and
proliferation of the inflammatory cells, together leading to the
increased growth of inflammation-associated cancers.
doi:10.1371/journal.pone.0006695.g008
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first antibody was deactivated by treatment with 3% H2O2. The
second primary antibody was detected using peroxidase-conjugat-
ed F(ab’)2 donkey anti-rabbit or anti-mouse IgG(H+L) (Jackson IR
Laboratories, West Grove, PA) followed by Alexa Flour 594
tyramide. Nuclei were identified using Hoechst 33258 (Sigma-
Aldrich, St. Louis, MO). Images were collected on a Leica SP2/
AOBS confocal microscope using a 636or 406oil immersion
objective NA 1.4, and processed using Leica TCS-SP software
(version 2.1537, Leica Microsystems, Exton, PA).
Enzyme-linked Immunosorbent Assay (ELISA)
CXCL16 was measured using a DuoSet ELISA Development
kit (R&D Systems), according to the manufacturer’s instructions.
Sorting of Lymphocyte Subsets and Stimulation
CD4
+ T cells were purified from elutriated lymphocytes by
negative selection with the RosetteSep reagents (StemCell
Technologies, Vancouver, BC). Subsets were sorted after staining
with fluorophore-conjugated anti-CD4, anti-CD45RO, and anti-
CXCR6. Cell sorting was done using a FACS Aria (BD
Biosciences), and the purity of sorted populations was 95–99%.
After sorting, cells were stimulated with 20 ng/ml PMA, and
1 mM ionomycin for 4 hours at 37uC before total cellular RNA
was isolated.
Proliferation of primary CD4
+ T cells with CXCL16
CD4
+ T cells purified from elutriated lymphocytes from healthy
donors were cultured in RPMI 1640 supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, penicillin and streptomycin.
Cells were stimulated for 3 days with plate-bound OKT3 (10 mg/
ml) with or without plate bound CXCL16 (PeproTech, Rocky
Hill, NJ) (5 mg/ml). Samples were analyzed using an LSRII flow
cytometer (BD Biosciences) after adding counting beads (SPHER-
O
TM AccuCount Fluorescent Particles, Spherotech Inc, Liberty-
ville, IL) together with 5 ml of Dead Cell Discriminator (CALTAG
Laboratories, Burlingame, CA). Numbers of proliferating cells
were determined using FlowJo software (Tree Star, Ashland, OR).
Migration of cells to CXCL16
Cells were washed and resuspended at a concentration of
1610
7 cells/ml in chemotaxis medium containing: RPMI 1640,
0.5% bovine serum albumin, 25 mM HEPES. A total of 1610
6
cells per 100 ml were loaded in the upper transwell chamber (pore
size, 5.0 mm; Costar, Corning, NY). Chemokine in 600 ml
chemotaxis medium was added to the lower chambers. Upper
chambers were transferred on top of lower chambers after a
30 min pre-incubation without chemokine at 37uCi n5 %C O 2
and were incubated for an additional two hours for chemotaxis.
The total contents of the lower chambers were collected and equal
numbers of counting beads (SPHERO
TM AccuCount Fluorescent
Particles, Spherotech) were added to each tube according to the
manufacturer’s instructions. Samples were run on an LSRII flow
cytometer (BD Biosciences) and fifty thousand events were
acquired to obtain numbers of migrating cells. Analysis was done
using FlowJo software (Tree Star).
Transfection for Expressing CXCR6-YFP Fusion Protein
The sequence encoding CXCR6 was inserted into the pEYFP-
N1 vector (Clontech Laboratories, Inc., Palo Alto, CA) to encode a
CXCR6 C-terminal fusion protein with an enhanced yellow-green
florescent protein (YFP). The plasmid encoding CXCR6-YFP or a
GFP control plasmid (pmaxGFP) (Amaxa, Gaithersburg, MD) was
introduced into cells using the Nucleofector
H Kit V according to
the manufacturer’s instructions (Amaxa).
Proliferation and Survival Assays
Twenty-four hours after transfecting cells to express either
CXCR6-YFP or GFP, cells were resuspended in 0–5 mg/ml
CXCL16 and harvested 48 hours later. For some experiments,
cells were loaded with 2 mM Far Red DDAO dye (7-hydroxy-9H
(I,3-dichloro-9,9-dimethylacridin-2-one) before culturing and for
some experiments harvested cells were stained with Annexin V-PE
(BD Biosciences) according to manufacturer’s instructions. Sam-
ples were analyzed using an LSRII flow cytometer (BD
Biosciences) after adding counting beads (SPHERO
TM Accu-
Count Fluorescent Particles, Spherotech) together with 5 mlo f
Dead Cell Discriminator (CALTAG Laboratories) or propidium
iodide. Numbers of live, dead, and in some cases proliferating and
non-proliferating cells were determined using FlowJo software
(Tree Star).
Statistical analysis
Data are expressed as the mean +/2 SEM. Statistical
comparisons of means were performed by unpaired Student’s t
test. For prostate array data, the Kruskal-Wallis or Mann-Whitney
tests were used. All statistical tests were two-sided.
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